1. Chan A, Poon E. Goh WL. Gan Y. Tan CJ. Yeo K, Chua A. Chee M. Law YC, Somasundaram N. Kanesvaran R. Ng QS. Tham CK, Tob CK, Lim ST, Tao M, Tang T. Quek R. Farid M. Assessment of psychological distress among Asian adolescents and young adults (AYA) cancer patients using the distress thermometer: a prospective, Iongitudinal study. Support Care Cancer 2018 Apr 11. [Epub ahead of print] JIF: 1.45
2. Yeo D, Hossain I, Lim ST, Farid M, Tao M, Quek R, Tang T. Chan A A response to the letter to the editor on "Management on hepatitis B reactivation in lymphoma patients on rituximab with past hepatitis B exposure: An observational study". J Oncol Pharm Pract. 2018 Sep; 24(6):478-479. JIF: 1.45
3. Chan JY, Ng AYJ, Chenq CL, Nairismagi ML, Venkatesh B, Cheah DMZ, Li ST, ChanSH. Ngee J, Laurensia Y . Lim JQ. Pang JWL, Nagarajan S, Song T, Chia B, Tan J, Hung D. Goh YT. Poon E, Somasundaram N, Tao M. Quek RHH, Farid M. Khor CC, Bei JX. Tan SY. Lim ST. Ong CK, Tang T. Whole exome sequencing identifies recessive germline mutations in FAM160A1 in familial NK/T cell lymphoma. Blood Cancer J. 2018 Nov 12:8(11):111. JIF: 8.125
4. Chan EHL. Koh LP. Lee J, De Mel S. Jexasekharan A. Liu X. Tang T. Lim ST. Tao M., Quek R. Farid Bin Harunal Ras M. Lee YS, Diona C, Tan D. Kim SJ. Chee YL. Poon MM. Real world experience of R-CHOP with or without consolidative radiotherapy vs DA-EPOCH-R in the first-line treatment of primary mediastinal B-cell lymphoma. Cancer Med. 2019 Jul 2 [Epub ahead of print| JIF: 3.362
5. Tan KM, Chia B. Lim JQ. Khoo LP. Cheng CL. Tan L. Poon E. Somasundaram N, prognostic model for nasal-type natural killer/T-cell lymphoma: A multicenter study. Science Reports. 2019 Oct 18. JIF: 4.122.
6. Chong LL, Wong EYT, Santos-Banta SLL, Cheng CL, Tan L, Poon EYL Somasundaram N Farid M. Tang T, Tao M, Khoo JBK, Shih V. Cheah DMZ7. Ong CK. Lim ST. Chan JY. Successful therapeutic rechallenge after a severe episode of high dose methotrexate-induced choreoathetosis: A case report. Mol Clin Oncol. 2019 Oct. JIF: 0.63
7. Lim RMH, Chan NPX, Khoo LP, Cheng CL, Tan L, Poon EYL, Somasundaram N, Farid M, Tang TPL, Tao M, Lim ST, Chan JY. A Clinico-Genotypic Prognostic Index for De Novo Composite Diffuse Large B-cell Lymphoma arising from Follicular Lymphoma in Asian patients treated in the Rituximab era. Sci Rep. 2020 Mar 9;10(1):4373. JIF: 3.998
8. Pwint KW, Chen Y, Diong CP, Goh YT, Grant D, Ho A, Hwang W, Kumar S, Lee YS, Lim F, Loh Y, Nagarajan C, Quek J, Tao M, Than H, Linn Yc. Mobilization kinetics of peripheral blood stem cells with rescue plerixafor – real-world experience from a single center. Leuk Lymphoma. 2020 Jul;61(7):1740-1743. JIF:1.71
9. Yap DRY, Tan GF, Chang EWY, Yang VS, Poon EYL, Somasundaram N, Farid M, Tang T, Tao M, Lim ST, Chan JY. Clinical Features of Plasmablastic Lymphoma: Case Series from an Asian Tertiary Cancer Center and Literature Review. J Hematol. 2020 Sep;9(3):71-78. JIF: 10.05
10. Tang T, Martin P, Somasundaram N, Lim C, Tao M, Poon E, Yunon MJ, Toh SQ, Yan SX, Farid M, Chan JY, Lim ST. Phase I study of selinexor in combination with dexamethasone, ifosfamide, carboplatin, etoposide chemotherapy in patients with relapsed or refractory peripheral T-cell or natarualkiller/T-cell lymphoma. Haematologica. 2020 Nov 5; Online ahead of print. JIF: 7.57
11. Tan CJ, Kumar R, Koomanan N, Loo WS, Farid M, Tao M, Somasundaram N, Poon E, Chan JY, Yang VS, Chang E, Lim ST, Chow WC, Chan A, Tang T. Clinical and economic evaluation of a surveillance protocol to manage hepatitis B virus (HBV) reactivation among lymphoma patients with resolved HBV infection receiving rituximab. Pharmacotherapy. 2021 Feb 6. JIF: 3.196
Clinical Trials
1. CMAK683X2101: A phase I/II, multicenter, open-label study of MAK683 in adult patients with advanced malignancies
2. Bayer 17067: A Phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of copanlisib in combination with rituximab in patients with relapsed indolent B-cell non-Hodgkin’s lymphoma
3. Bayer 17833: 2-arm, placebo-controlled Phase III trial of intravenous PI3K inhibitor Copanlisib in combination with standard immunochemotherapy in patients with relapsed indolent NHL
4. 54767414NKT2001 : An Open Label, Phase 2 Study to assess the Clinical Efficacy and Safety of Daratumumab in Patients With Relapsed or Refractory Natural Killer/T-Cell Lymphoma, Nasal Type
5. MOR208C204: A Phase III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT)
